Limited effects of antibiotic prophylaxis in patients with Child–Pugh class A/B cirrhosis and upper gastrointestinal bleeding

Te-Sheng Chang1,2,3, Ying-Huang Tsai2,4, Yi-Heng Lin3,5, Chun-Hsien Chen1, Chung-Kuang Lu1, Wen-Shih Huang2,6, Yao-Hsu Yang2,7,8, Wei-Ming Chen1,2, Yung-Yu Hsieh1,2, Yu-Chih Wu5, Shui-Yi Tung1,2,*, Yen-Hua Huang1,2,*,10,11,12

1 Department of Gastroenterology and Hepatology, Chang Gung Memorial Hospital, Chiayi, Taiwan, 2 College of Medicine, Chang Gung University, Taoyuan, Taiwan, 3 Department of Biochemistry and Molecular Cell Biology, College of Medicine, Taipei Medical University, Taipei, Taiwan, 4 Department of Pulmonary and Critical Care Medicine, Chang Gung Memorial Hospital, Chiayi, Taiwan, 5 Research Center for Cell Therapy and Regeneration Medicine, Taipei Medical University, Taipei, Taiwan, 6 Division of Colon and Rectal Surgery, Department of Surgery, Chang Gung Memorial Hospital, Chiayi, Taiwan, 7 Department of Traditional Chinese Medicine, Chang Gung Memorial Hospital, Chiayi, Taiwan, 8 Health Information and Epidemiology Laboratory of Chang Gung Memorial Hospital, Chiayi, Taiwan, 9 Graduate Institute of Medical Sciences, College of Medicine, Taipei Medical University, Taipei, Taiwan, 10 Center for Reproductive Medicine, Taipei Medical University Hospital, Taipei, Taiwan, 11 Comprehensive Cancer Center of Taipei Medical University, Taipei, Taiwan, 12 International PhD Program for Cell Therapy and Regeneration Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan.

* rita1204@tmu.edu.tw (YHH); ma1898@cgmh.org.tw(S YT)

Abstract

Current guidelines recommend antibiotic prophylaxis for all patients with various degrees of cirrhosis and upper gastrointestinal (UGI) bleeding. This study assessed the need for antibiotic prophylaxis in patients with low Child–Pugh scores. We retrospectively screened all patients with cirrhosis who underwent upper endoscopies for UGI bleeding in a referral hospital in Taiwan between 2003 and 2014, from which 913 patients were enrolled after excluding patients with active bacterial infections, recent antibiotic use, early death, and Child–Pugh class C cirrhosis. Among them, 73 (8%) received prophylactic antibiotics, and 45 (4.9%) exhibited 14-day bacterial infection. Neither Child–Pugh score nor model for end stage liver disease score were optimal for predicting bacterial infection because their areas under the curves were 0.610 (95% confidence interval [CI]: 0.529–0.691) and 0.666 (95% CI: 0.591–0.742), respectively. Antibiotic prophylaxis did not reduce the risks of 14-day bacterial infection (relative risk [RR]: 0.932, 95% CI: 0.300–2.891, P = 0.902), 14-day rebleeding (RR: 0.791, 95% CI: 0.287–2.181, P = 0.650), or 42-day mortality (RR: 2.710, 95% CI: 0.769–9.524, P = 0.121). The results remained similar after propensity score adjustment. On-demand antibiotic treatment might suffice for patients with Child–Pugh class A/B cirrhosis and UGI bleeding.
Introduction

Patients with cirrhosis are considered immunocompromised and susceptible to various bacterial infections that may aggravate the major complications of cirrhosis [1]. Therefore, preventing infections is considered a constitutive part of patient care, and all the relevant practice guidelines and consensus statements recommend antibiotic prophylaxis for all patients with cirrhosis in specific settings, including secondary prophylaxis for patients with previous spontaneous bacterial peritonitis (SBP) and primary prophylaxis for patients with poor liver function and those with active upper gastrointestinal (UGI) bleeding [2–4]. The role of prophylactic antibiotics is critical in patients with cirrhosis and UGI bleeding because bacterial infections during or immediately after bleeding episodes are associated with severe complications, such as failure to control bleeding, rebleeding, and mortality during hospitalization [5–7].

Prophylactic antibiotics have substantial benefits in patients with cirrhosis and UGI bleeding; consequently, prophylactic antibiotics have been endorsed by major clinical practice guidelines [2–4]. However, excessive antibiotic use is associated with side effects, including drug toxicity, drug–drug interaction, and *Clostridium difficile* infection [8]. Moreover, a recent study demonstrated that antibiotic prophylaxis in hospitalized patients with cirrhosis may increase the risk of subsequent infection [9]. Therefore, a balance of the risks and benefits of routine and indiscriminate prophylactic antibiotic use in all patients with cirrhosis and UGI bleeding is essential. In the 2000s, numerous patients with cirrhosis-related ascites did not receive recommended services, including prophylactic antibiotics, during UGI bleeding [10]. Taking advantage of this situation, the authors of the present study have observed that not all patients had identical bacterial infection risk without prophylactic antibiotic use.

In patients with cirrhosis and portal hypertension, risk stratification and personalized care have become primary strategies in the current stratified medicine era [4,11]. In recent years, patients with cirrhosis of varying severity may have disparate levels of risk of complications during UGI bleeding; therefore, such patients have varying needs for prophylactic antibiotics [12,13]. The risk of cirrhosis-related complications, including gastroesophageal variceal hemorrhage, mainly depends on the degree of portal hypertension, which is proportional to the severity of cirrhosis [14]. The Child–Pugh score is the simplest and most effective tool for assessment of bedside prognosis in patients with cirrhosis [12,15]. In this study, we reappraised whether a stratified, rather than indiscriminate, prophylactic antibiotic use strategy, based on the Child–Pugh score, is applicable in patients with cirrhosis and UGI bleeding.

Materials and methods

Study patients and data collection

In this retrospective study, we analyzed all patients with cirrhosis aged ≥ 20 years who underwent upper endoscopy for UGI bleeding between January 2003 and December 2014 at Chang Gung Memorial Hospital, a tertiary referral hospital in Chiayi, southern Taiwan. Data were retrieved from the hospital’s computer archives; the electronic medical records of all eligible patients were reviewed to obtain necessary data, including clinical data, demographic characteristics, and laboratory examination results. The study endpoints included 14-day infection and rebleeding rates and 42-day mortality rate. All patient records were traced until day 42 (end of week 6) or death. The exclusion criteria were (1) bacterial infection on the day of UGI bleeding, (2) antibiotic use within 1 week before UGI bleeding, (3) Child–Pugh class C (score ≥ 10), and (4) death within the first 24 h. To prevent the recording of redundant demographic variables, only the first UGI bleeding episode in patients with multiple UGI bleeding
episodes was included for analysis as the index bleeding episode. Because the present study was retrospective without specific interventions for the study patients, the requirement for informed consent was waived. All patient data were fully anonymized before access and this study was approved by the Chang Gung Medical Foundation Institutional Review Board (IRB No: 201701786B0).

Management program

Since the inauguration of Chang Gung Memorial Hospital, Chiayi branch (i.e., the study site) in 2002, upper endoscopy using a video endoscope (GIF-Q240Z, Olympus, Tokyo, Japan) and an electronic endoscopic system, either the EVIS 240 series (Olympus) or the EVIS 260 series (Olympus) with endoscopic hemostasis within 24 h (usually within 12 h) has been the standard of care for all patients with UGI bleeding due to any etiology. Endoscopic hemostasis is achieved using measures, including band ligation, injection sclerosis, and coagulation, depending on the clinical scenario and operators’ decisions. The vasoactive drug terlipressin (Glypressin, Ferring AB, Malmö, Sweden) with or without intravenous proton pump inhibitor (PPI) use is generally initiated before endoscopy if the medical history and clinical picture suggests portal hypertension. After endoscopy, patients receive terlipressin at 1 mg/6 h for 3 days for UGI bleeding due to portal hypertension and intravenous PPI (omeprazole or pantoprazole 80 mg bolus loading and 40 mg twice daily for 1–3 days) due to peptic ulcers. Oral PPI is given for 2–4 months for patients with peptic ulcer disease. Patients may undergo repeat endoscopy or surgical devascularization if the initial endoscopic therapy fails. Secondary prophylaxis with the oral β-blocker propranolol is initiated as soon as variceal bleeding stops, provided no contraindication is noted. Decisions regarding the use and choice of prescribed antibiotics are taken by the clinicians in charge, most of whom are from the emergency department.

Definition

We defined antibiotic prophylaxis as antibiotic prescription following bleeding in the absence of clinical signs of bacterial infection. Liver cirrhosis was diagnosed on the basis of the presence of esophageal or gastric varices observed through endoscopy with compatible image characteristics and clinical features indicating portal hypertension, such as splenomegaly, hepatic dysfunction, or thrombocytopenia. The patients were classified according to liver disease etiologies, namely hepatitis B virus (HBV) hepatitis (presence of the HBV surface antigen in the serum), hepatitis C virus (HCV) hepatitis (presence of the HCV antibody in the serum), dual HBV and HCV hepatitis (BC) hepatitis (presence of both HBV and HCV), and non-BC hepatitis (NBNC; negative for both HBV and HCV). The cause of UGI bleeding, either portal hypertension (gastric or esophageal varices) or peptic ulcers, was determined after endoscopy revealed active bleeding or stigmata of recent hemorrhage accompanied by a reduction in hemoglobin levels. Rebleeding was diagnosed when bleeding recurred more than 24 h after the initial bleeding episode had been controlled. The diagnoses of bacterial infections were made based on the standard guidelines [16]. In addition, SBP was defined as an ascites polymorphonuclear cell count of ≥250 cells/mm³ and/or positive ascitic fluid culture. Common skin flora, particularly coagulase-positive staphylococci, was considered contaminants unless blood cultures were positive on two or more occasions or clinical signs of the relevant infection were observed.

Statistical analysis

Continuous variables are expressed as means ± standard deviations. The qualitative and quantitative differences between the groups were analyzed using the chi-square or Fisher exact test.
for categorical parameters and the Student t test for continuous parameters. The multivariate logistic regression model was used to identify independent risk factors. Receiver operating characteristic (ROC) curves were employed to assess the performance characteristics of the Child–Pugh and model for end-stage liver disease (MELD) scores in predicting the acquisition of infection. All statistical tests were performed using SPSS (version 22.0; IBM, Chicago, IL, USA). A two-tailed \( P < 0.05 \) was considered significant. Because antibiotics are theoretically more likely to be prescribed to patients with more severe cirrhosis, propensity scores (PPS) were calculated using antibiotic prophylaxis as the outcome variable in a multivariate logistic regression model.

**Results**

**Patient characteristics**

Fig 1 presents the flow of all included patients. In total, 1741 patients presented to the study site and had 4059 UGI bleeding episodes between January 2003 and December 2014. After the exclusion of 102 patients with active bacterial infections, 130 with recent antibiotic use, 37 who died within 24 h, and 559 with Child–Pugh class C scores, the remaining 913 were enrolled for analysis. Of these 913 patients, 73 received antibiotic prophylaxis and 840 did not. Of the 73 patients who received antibiotic prophylaxis, 19 received cefazolin, 4 received cefazolin plus gentamicin, 6 received cefuroxime, and 44 received ceftriaxone. The baseline characteristics of these 913 patients with Child–Pugh A/B scores are listed in Table 1. Their mean age was 59.49 ± 13.15 years, and the male-to-female ratio was 2.42:1. Those who received antibiotic prophylaxis were younger (55.22 ± 12.46 vs. 59.86 ± 13.15 years, \( P = 0.003 \)), had more units of blood transfusion (3.38 ± 2.78 vs. 2.43 ± 2.44 units, \( P = 0.006 \)), had higher white blood cell counts (9.87 ± 4.28 vs. 7.92 ± 4.18 × 10^3/μL, \( P < 0.001 \)), had lower systolic blood pressure (112.47 ± 27.24 vs. 121.37 ± 31.03 mmHg, \( P = 0.007 \)), had a higher rate of intensive care unit admission (9.6% vs. 2.3%, \( P < 0.001 \)), and had a higher rate of portal hypertensive-related (variceal) bleeding (93.10% vs. 77.14%, \( P = 0.001 \)). The patients who received and did not receive antibiotic prophylaxis did not differ significantly in terms of sex, presence of hepatocellular carcinomas (HCCs), Child–Pugh scores, MELD scores, prior SBP, duration of hospitalization, and rates of 14-day infection, 14-day rebleeding, and 42-day mortality. Because this study was conducted over a long 12-year period, we divided the patients into two groups according to the period of UGI bleeding to understand whether there were differences in patient characteristics over time. As shown in Table 2, compared with patients who presented between 2003 and 2008, patients who presented between 2009 and 2014 were older (58.43 ± 12.98 vs. 60.70 ± 13.26 years, \( P = 0.009 \)), had a higher rate of prophylactic antibiotic use (2.9% vs. 13.8%, \( P < 0.001 \)), had shorter duration of hospitalization (6.92 ± 5.24 vs. 6.21 ± 5.71 days, \( P = 0.05 \)), and had a lower Child–Pugh score (7.40 ± 1.18 vs. 7.22 ± 1.22, \( P = 0.0027 \)). A similar insignificant difference in rates of 14-day infection, 14-day rebleeding, and 42-day mortality was observed separately in both Child–Pugh class A and class B patients (S1 Table). We also analyzed the 716 patients with portal hypertensive bleeding as a separate group, and the baseline characteristics of these patients are listed in S2 Table.

**Factors associated with risk of 14-day infection**

During the 11-year observation period, only 45 (4.9%) of the enrolled 913 patients exhibited confirmed bacterial infection within 14 days of presentation at the hospital (Table 3). Table 4 lists bacterial infection types in these 45 patients. No significant reduction was observed in the risk of acquiring bacterial infection in the patients who received antibiotic prophylaxis compared with those who did not (relative risk [RR]: 0.932, 95% confidence interval [CI]: 0.300–
Fig 1. Flow of patient enrollment.

https://doi.org/10.1371/journal.pone.0229101.g001
There was also no significant difference in infection risk with respect to prophylactic antibiotic use when Child–Pugh class A and class B patients were analyzed separately (S3 Table). Except for white blood cell counts (RR: 1.102, 95% CI: 1.016–1.194, \( P = 0.019 \)), platelet counts (RR: 0.991, 95% CI: 0.983–0.998, \( P = 0.019 \)), albumin levels (RR: 0.434, 95% CI: 0.195–0.965, \( P = 0.041 \)), and MELD scores (RR: 1.132, 95% CI: 1.033–1.241, \( P = 0.008 \)), all
clinical and laboratory parameters—including age, sex, ascites, previous SBP, blood pressure, hemoglobin levels, presence of HCC, intensive care unit admission, Child–Pugh score, etiology of cirrhosis, cause of UGI bleeding, and endoscopic therapy—did not affect the RR of bacterial infection (Table 3). After PPS adjustment with antibiotic prophylaxis as the outcome variable, 138 patients who received and did not receive antibiotic prophylaxis were obtained at a ratio of 1:1, forming two groups with 69 patients each. Among the 138 patients, 9 had bacterial infection; risk of infection did not differ significantly between those who received and did not receive antibiotic prophylaxis (RR: 0.962, 95% CI: 0.147–6.288, \( P = 0.968 \)). Fig 2 presents the ROC curves and areas under the ROC curves (AUCs) of the Child–Pugh and MELD scores for predicting bacterial infection. Among the patients with cirrhosis with Child–Pugh scores of 5–9 and UGI bleeding, neither the Child–Pugh score nor the MELD score was an optimal tool for predicting bacterial infection because the AUCs (95% CIs) were 0.610 (0.529–0.691) and 0.666 (0.591–0.742), respectively—both <0.7. When only the 716 portal hypertensive bleeding patients were included, the risk of 14-day infection did not differ significantly between those who received and did not receive antibiotic prophylaxis (RR: 0.827, 95% CI: 0.233–2.937, \( P = 0.769 \)) as shown in S4 Table.

**Factors associated with risk of 14-day rebleeding**

In this study, 76 of the 913 original patients and 12 of the 138 PPS-matched patients experienced rebleeding within 14 days of presentation at the hospital. Table 5 summarizes the RRs of all factors associated with this rebleeding. Among the 913 patients, the factors significantly affecting the RRs of rebleeding were units of blood transfusion (RR: 1.185, 95% CI: 1.055–1.332, \( P = 0.004 \)), albumin levels (RR: 0.500, 95% CI: 0.255–0.981, \( P = 0.004 \)), and treatment

### Table 2. Changes in patient characteristics and results over time.

|                      | 2003–2008 (n = 487) | 2009–2014 (n = 426) | \( P \)^† |
|----------------------|---------------------|---------------------|------------|
| Age, mean ± SD (years) | 58.43 ± 12.98       | 60.70 ± 13.26       | 0.009      |
| Sex, male n (%)       | 351 (72.1)          | 298 (70)            | 0.527      |
| Prophylaxis, n (%)     | 14 (2.9)            | 59 (13.8)           | <0.001     |
| Hepatocellular carcinoma, n (%) | 159 (32.6) | 147 (34.5)         | 0.601      |
| Blood transfused in 48 h, unit | 2.45 ± 2.47 | 2.57 ± 2.48        | 0.475      |
| Ascites, n (%)         | 203 (41.7)          | 174 (40.8)          | 0.850      |
| Hepatic encephalopathy, n (%) | 27 (5.5)   | 20 (4.7)           | 0.668      |
| Platelet count, \( \times 10^9/\mu L \) | 110.58 ± 76.93 | 114.55 ± 61.44     | 0.393      |
| Hemoglobin, g/L        | 9.32 ± 2.31         | 9.10 ± 2.69         | 0.187      |
| Creatinine, mg/L       | 1.28 ± 1.22         | 1.21 ± 1.21         | 0.762      |
| Hospitalization days   | 6.92 ± 5.24         | 6.21 ± 5.71         | 0.05       |
| MELD score             | 12.69 ± 3.76        | 12.40 ± 3.66        | 0.246      |
| Child–Pugh score       | 7.40 ± 1.18         | 7.22 ± 1.22         | 0.027      |
| Infection within 14 days, n (%) | 33 (6.8)  | 12 (2.8)           | 0.09       |
| Rebleeding within 14 days, n (%) | 39 (8)     | 37 (8.7)          | 0.803      |
| Mortality within 42 days, n (%) | 18 (3.7)    | 14 (3.3)          | 0.722      |
| Body mass index (kg/m\(^2\)) | 24.87 ± 3.71 | 24.85 ± 3.88       | 0.918      |
| Diabetes mellitus, n (%) | 163 (33.5) | 169 (39.7)        | 0.061      |
| ICU admission, n (%)   | 11 (2.3)            | 15 (3.5)            | 0.345      |

^† Comparison between patients enrolled during 2003–2008 and 2009–2014.

Abbreviations: SD, standard deviation; ICU, intensive care unit; MELD, model for end-stage liver disease.

https://doi.org/10.1371/journal.pone.0229101.t002

Antibiotics for cirrhosis with UGI bleeding

PLOS ONE | https://doi.org/10.1371/journal.pone.0229101 February 21, 2020 7 / 16
with endoscopic variceal ligation (RR: 0.455, 95% CI: 0.240–0.865, \(P = 0.016\)). Antibiotic prophylaxis did not affect the RR of rebleeding (RR: 0.791, 95% CI: 0.287–2.181, \(P = 0.650\)) (Table 5 and S3 Table). The risk of 14-day rebleeding did not differ significantly between the patients who received and did not receive antibiotic prophylaxis after PPS adjustment (RR: 0.292, 95% CI: 0.050–1.171, \(P = 0.173\)). When only the 716 portal hypertensive bleeding patients were included, the risk of 14-day rebleeding did not differ significantly between those who received and did not receive antibiotic prophylaxis (RR: 0.696, 95% CI: 0.223–2.170, \(P = 0.533\)) as shown in S5 Table.

### Factors associated with the risk of 42-day mortality

Among the 913 original patients and 138 PPS-matched patients, 32 and 6 exhibited 42-day mortality, respectively. In the 32 patients, the causes of mortality were potentially multifactorial,
| Type       | No | Site and bacteria       | Abbreviations                  |
|------------|----|-------------------------|-------------------------------|
| SBP        | 7  | Blood                   | Ascites                       |
|            | 1  | *Bacteroides thetaiotaomicron* | *Bacteroides thetaiotaomicron* |
|            | 2  | *Escherichia coli*       |                               |
|            | 1  | *Group B streptococci*   |                               |
|            | 1  | -                       | *Viridans streptococci*       |
| Pneumonia  | 7  | Blood                   | Sputum                        |
|            | 2  | -                       | *Haemophilus influenza*        |
|            | 1  | -                       | *Acinetobacter baumannii*     |
| UTI        | 12 | Blood                   | Urine                         |
|            | 1  | *Acinetobacter baumannii* |                               |
|            | 1  | *Escherichia coli*       |                               |
|            | 1  | *Klebsiella pneumoniae*  | *Serratia marcescens*         |
|            | 1  | *Acinetobacter baumannii* |                               |
|            | 1  | -                       | *Coagulase-negative staphylococci* |
|            | 1  | -                       | *Klebsiella pneumoniae*       |
|            | 1  | *Escherichia coli*       |                               |
|            | 1  | *Bacillus spp.*          | *Enterococcus faecalis*       |
|            | 1  | *Escherichia coli*       | *Escherichia coli*            |
|            | 3  | -                       |                               |
| Cellulitis | 2  | Blood                   |                               |
|            | 1  | *Staphylococcus aureus*  |                               |
|            | 1  | *Klebsiella pneumoniae*  |                               |
| Arthritis  | 2  | Blood                   | Synovial fluid                |
|            | 1  | -                       | *Staphylococcus aureus*       |
| Unknown    | 15 | Blood                   |                               |
|            | 1  | *Stenotrophomonas maltophilia* |                               |
|            | 2  | *Klebsiella pneumoniae*  |                               |
|            | 1  | *Salmonella enterica*    | *Serogroup B*                 |
|            | 1  | -                       | *Viridans streptococci*       |
|            | 3  | *Staphylococcus aureus*  | *Peptostreptococcus spp.*     |
|            | 1  | *Aeromonas caviae*       |                               |
|            | 1  | *Vibrio vulnificus*      |                               |
|            | 2  | *Escherichia coli*       |                               |
|            | 2  | -                       | *Viridans streptococci*       |
|            | 1  | *Streptococcus pneumoniae* |                               |
|            | 1  | -                       | *Enterobacter cloacae*        |

**Abbreviations:** SBP, spontaneous bacterial peritonitis; UTI, urinary tract infection; ORSA, oxacillin-resistant *Staphylococcus aureus*.

https://doi.org/10.1371/journal.pone.0229101.t004
with major causes being infection, refractory bleeding, aortic dissection, acute myocardial infarction, and acute on chronic liver failure in 7, 4, 1, 1, and 19 patients, respectively. The 42-day mortality rate was approximately 3.5% in the patients with Child–Pugh A/B cirrhosis and UGI bleeding. As shown in Table 6, except for the presence of HCCs (RR: 5.300, 95% CI: 1.850–15.187, \( P = 0.002 \)) and platelet counts (RR: 1.006, 95% CI: 1.002–1.010, \( P = 0.003 \)), no clinical and laboratory parameters, including antibiotic prophylaxis (RR: 2.710, 95% CI: 0.769–9.524, \( P = 0.121 \)), affected the RR of 42-day mortality. Antibiotic prophylaxis similarly did not significantly affect risk of 42-day mortality in Child–Pugh Class B patient subgroup (RR: 2.681, 95% CI: 0.761–9.434, \( P = 0.125 \); S3 Table). Because the number of cases of 42-day mortality was low in the PPS-matched cohort, the RRs and their corresponding 95% CIs were incalculable for all factors. However, no factors, including antibiotic prophylaxis, significantly affected the RRs of 42-day mortality. Antibiotic prophylaxis similarly did not significantly affect risk of 42-day mortality in Child–Pugh B patient subgroup (RR: 2.681, 95% CI: 0.761–9.434, \( P = 0.125 \); S3 Table). Because the number of cases of 42-day mortality was low in the PPS-matched cohort, the RRs and their corresponding 95% CIs were incalculable for all factors. However, no factors, including antibiotic prophylaxis, significantly affected the RRs of 42-day mortality after adjustment for PPS (\( P = 0.994–1.000 \)). The use of prophylactic antibiotics did not affect the 42-day mortality (RR: 2.304, 95% CI: 0.558–9.521, \( P = 0.249 \)) when only the 716 portal hypertensive bleeding patients were included for analysis as demonstrated in S6 Table.

Discussion

Antibiotic overuse is a pressing public health issue in current medical practices because antibiotics can lead to life-threatening complications [8,17]. Thus, an effective antibiotic stewardship program requires restricting antibiotic use to subpopulations at an extremely high bacterial infection risk as well as avoiding inappropriate antibiotic use [17].

In clinical care for patients with cirrhosis, bacterial infection is typically a frequent and severe complication, and prophylactic antibiotic use is an integral part of patient care, particularly in patients with UGI bleeding [18]. Over the preceding three decades, studies investigating the role of antibiotic prophylaxis in patients with cirrhosis and UGI bleeding have demonstrated that antibiotic prophylaxis can reduce rates of bacterial infection, rebleeding, and mortality in patients with cirrhosis and UGI bleeding [6]. Thus, all current practice.
guidelines and consensus statements recommend antibiotic prophylaxis for all patients with cirrhosis and active UGI bleeding [2–4]. However, most studies on the role of antibiotic prophylaxis in patients with cirrhosis who have UGI bleeding have not considered the differences in bacterial infection risk levels in patients with varying degrees of liver cirrhosis [6].

Patients with Child–Pugh class C cirrhosis have an extremely high risk of bacterial infection, and prophylactic antibiotic use in such patients is justified, because more than half of our class C patients exhibited either documented bacterial infection or clinical signs of bacterial infection within days of UGI bleeding. However, patients with cirrhosis and low liver function impairment, namely those with Child–Pugh class A/B, are at a relatively low risk of bacterial infection, and such infections are generally less severe than those in patients with cirrhosis and high liver function impairment [19]. A recent study in Canada demonstrated that patients

Table 5. Factors associated with risk of rebleeding within 14 days.

| Factors                  | All patients (n = 913) | PPS-matched patients (n = 138) |
|--------------------------|------------------------|-------------------------------|
|                          | RR         | 95% CI   | P             | RR         | 95% CI   | P             |
| Prophylaxis              | 0.791      | 0.287–2.18 | 0.650        | 0.292      | 0.050–1.17 | 0.173        |
| Age, years               | 0.992      | 0.287–2.18 | 0.483        | 0.990      | 0.905–1.083 | 0.825        |
| Sex, male/female         | 1.891      | 0.9807–3.648 | 0.057       | 11.969     | 0.737–194.294 | 0.081 |
| Prior SBP, y/n           | –          | –        | 0.998        | –          | –        | 0.999        |
| Ascites, y/n             | 1.944      | 0.950–3.980 | 0.069       | 0.524      | 0.022–12.606 | 0.690        |
| HCCs, y/n                | 1.131      | 0.640–1.998 | 0.672       | 0.461      | 0.047–4.564 | 0.508        |
| Blood transfusion, unit  | 1.185      | 1.055–1.332 | 0.004       | 1.242      | 0.861–1.792 | 0.247        |
| Encephalopathy, y/n      | 0.690      | 0.189–2.514 | 0.573       | 1.166      | 0.057–23.708 | 0.920        |
| Blood pressure, mmHg     | 0.996      | 0.987–1.005 | 0.379       | 1.104      | 0.968–1.403 | 0.320        |
| Hemoglobin, g/L          | 1.039      | 0.909–1.187 | 0.578       | 1.057      | 0.649–1.721 | 0.824        |
| WBC count, ×10⁹/µL       | 0.927      | 0.853–1.008 | 0.076       | 0.828      | 0.621–1.015 | 0.200        |
| Platelet count, ×10⁹/µL  | 1.002      | 0.999–1.006 | 0.240       | 1.103      | 0.995–1.032 | 0.168        |
| Albumin, g/dL            | 0.500      | 0.255–0.981 | 0.004       | 0.988      | 0.097–10.106 | 0.992        |
| ICU admission, y/n       | 0.914      | 0.236–3.530 | 0.896       | 0.426      | 0.014–12.662 | 0.622        |
| MELD score               | 0.910      | 0.910–0.831 | 0.042       | 0.674      | 0.447–1.016 | 0.059        |
| Child Pugh score         | 0.978      | 0.657–1.455 | 0.912       | 5.330      | 0.827–34.348 | 0.078        |
| Etiology of cirrhosis    |            | 0.262     |              |            | 0.421     |              |
| NBNC                     | 1.000      |           |              | 1.000      |           |              |
| HBV                      | 1.019      | 0.411–2.527 | 0.968       | 7.168      | 0.420–122.290 | 0.174        |
| HCV                      | 1.830      | 0.831–4.027 | 0.133       | 2.762      | 0.156–48.989 | 0.489        |
| BC                       | 1.750      | 0.641–4.777 | 0.275       | 0.754      | 0.014–40.663 | 0.885        |
| Treatment                |            | 0.098     |              |            | 0.669     |              |
| No treatment             | 1.000      |           |              | 1.000      |           |              |
| APC                      | 0.991      | 0.334–2.944 | 0.988       | –         | –        | 0.999        |
| EVL                      | 0.455      | 0.240–0.865 | 0.016       | 3.403      | 0.165–70.014 | 0.427        |
| EIS                      | 0.809      | 0.367–1.782 | 0.599       | 6.578      | 0.311–139.036 | 0.226        |
| Etiology of bleeding     |            | 0.294     |              |            | 0.213     |              |
| Portal hypertension      | 1.000      |           |              | 1.000      |           |              |
| Peptic ulcer             | 0.585      | 0.214–1.599 | 0.114       | 11.041     | 0.250–496.156 | 0.173 |

† Number of patients with 14-day rebleeding: 76 of all 913 patients and 12 of the 138 PPS-matched patients.

Abbreviations: PPS, propensity score; RR, relative risk; CI, confidence interval; y/n, yes/no; SBP, spontaneous bacterial peritonitis; HCC, hepatocellular carcinoma; WBC, white blood cell; ICU, intensive care unit; MELD, model for end-stage liver disease; NBNC, negative for both HBV and HCV; HBV, hepatitis B virus; HCV, hepatitis C virus; BC, presence of both HBV and HCV; APC, argon plasma coagulation; EVL, endoscopic variceal ligation; EIS, endoscopic injection sclerosis.
with Child–Pugh class A cirrhosis and acute variceal bleeding had low bacterial infection and mortality rates without receiving antibiotic prophylaxis [11]. The prophylactic effects of ceftriaxone were superior to those of cefazolin in terms of preventing infection and rebleeding only in patients categorized as Child–Pugh class B/C; this finding is indirect evidence for the low risk of bacterial infection in patients with Child–Pugh class A cirrhosis [20]. These observations provided the rationale for our study to reappraise the effects of antibiotic prophylaxis in patients with low Child–Pugh scores and UGI bleeding.

In addition to patients with Child–Pugh class C cirrhosis, we excluded those with documented bacterial infection on the day of UGI bleeding, with recent antibiotic use within 1 week before the UGI bleeding episode, and who died within the first 24 h, because these patients may have received or would have inevitably received antibiotic therapy for their clinical conditions. Most of these excluded patients also had Child–Pugh class C cirrhosis.

### Table 6. Factors associated with risk of mortality within 42 days

| Factors                  | All patients (n = 913) | PPS match (n = 138) |
|-------------------------|-----------------------|---------------------|
|                         | RR        | 95% CI        | P     | RR        | 95% CI        | P     |
| Prophylaxis, y/n        | 2.710     | 0.769–9.524   | 0.121 | –         | –             | 0.998 |
| Age, years              | 0.991     | 0.951–1.032   | 0.656 | –         | –             | 0.994 |
| Sex, male/female        | 0.860     | 0.295–2.508   | 0.782 | –         | –             | 0.998 |
| Prior SBP, y/n          | –         | –             | –     | 0.998     | –             | 1.000 |
| Ascites, y/n            | 0.994     | 0.329–3.001   | 0.992 | –         | –             | 0.999 |
| HCCs, y/n               | 5.300     | 1.850–15.187  | 0.002 | –         | –             | 0.997 |
| Blood transfusion, unit | 1.085     | 0.901–1.305   | 0.389 | –         | –             | 0.999 |
| Encephalopathy, y/n     | 2.218     | 0.575–8.557   | 0.247 | –         | –             | 0.999 |
| Blood pressure, mmHg    | 0.997     | 0.982–1.013   | 0.736 | –         | –             | 0.997 |
| Hemoglobin, g/L         | 1.043     | 0.830–1.309   | 0.720 | –         | –             | 1.000 |
| WBC count, ×10^3/μL     | 0.915     | 0.807–1.038   | 0.169 | –         | –             | 0.999 |
| Platelet count, ×10^3/μL| 1.006     | 1.002–1.010   | 0.003 | –         | –             | 1.000 |
| Albumin, g/dL           | 0.407     | 0.143–1.154   | 0.091 | –         | –             | 1.000 |
| ICU admission, y/n      | 4.338     | 0.997–18.867  | 0.050 | –         | –             | 1.000 |
| MELD score              | 1.098     | 0.966–1.249   | 0.153 | –         | –             | 0.999 |
| Child Pugh score        | 1.899     | 0.972–3.710   | 0.061 | –         | –             | 0.995 |
| Etiology of cirrhosis   | 0.539     | –             | –     | 0.999     | –             | 1.000 |
|                         | 1.000     | 1.000        |       | 1.000     | 1.000         |       |
| NBNBC                   | 1.000     | –             | –     | 0.999     | –             | 1.000 |
| HBV                     | 1.189     | 0.411–2.527   | 0.824 | –         | –             | 1.000 |
| HCV                     | 0.687     | 0.153–3.092   | 0.625 | –         | –             | 0.999 |
| BC                      | 1.849     | 0.330–10.369  | 0.485 | –         | –             | 1.000 |
| Treatment               | 0.610     | –             | –     | 0.999     | –             | 1.000 |
| No treatment            | 1.000     | 1.000        |       | 1.000     | 1.000         |       |
| APC                     | 0.433     | 0.073–2.568   | 0.357 | –         | –             | 1.000 |
| EVL                     | 1.609     | 0.452–5.731   | 0.463 | –         | –             | 0.999 |
| EIS                     | 0.908     | 0.162–5.103   | 0.913 | –         | –             | 0.995 |
| Etiology of bleeding    | 0.293     | –             | –     | 1.000     | –             | 1.000 |
| Portal hypertension     | 1.000     | –             | –     | 0.999     | –             | 1.000 |
| Peptic ulcer            | 2.351     | 0.478–11.500  | –     | –         | –             | 1.000 |

† Number of patients with 42-day mortality: 32 of all 913 patients and 6 of the 138 PPS-matched patients.

Abbreviations: PPS, propensity score; RR, relative risk; CI, confidence interval; y/n, yes/no; SBP, spontaneous bacterial peritonitis; HCC, hepatocellular carcinoma; WBC, white blood cell; ICU, intensive care unit; MELD, model for end-stage liver disease; NBNC, negative for both HBV and HCV; HBV, hepatitis B virus; HCV, hepatitis C virus; BC, presence of both HBV and HCV; APC, argon plasma coagulation; EVL, endoscopic variceal ligation; EIS, endoscopic injection sclerosis.

https://doi.org/10.1371/journal.pone.0229101.t006
Most related studies only enrolled patients with variceal bleeding, and most of these patients exhibited alcoholism. By contrast, our study population comprised patients at ratios of 4:1 for viral versus nonviral (majorly alcoholic) cirrhosis and variceal versus peptic ulcer bleeding (Table 1). Our results demonstrated that neither the etiology of cirrhosis nor the cause of UGI bleeding affected the patients’ major outcomes. A recent study suggested that active alcohol drinkers have a high infection risk [12]. By contrast, patients with nonviral cirrhosis had the lower risk for infection in this study. This inconsistency warrants further investigation because our retrospective clinical information did not contain precise data regarding active drinking. Furthermore, the modality of endoscopic therapy did not affect the patient outcomes.

In our study, the proportion of patients who received antibiotic prophylaxis was only 8% (73 of 913 patients with Child–Pugh class A/B cirrhosis)—consistent with a Taiwanese study, where only 6.7% patients with cirrhosis and acute variceal bleeding received prophylactic antibiotics between 2005 and 2006 [21]. Even in Western studies, the percentages of patients receiving prophylactic antibiotics have been <50% [7,10,11]. Thus, antibiotic prophylaxis may not be a common practice in both Western countries and Taiwan in the 2000s, with rates ranging from 6.67% to 49.2% [7,10,12,21].

Our data revealed that 19.6% (165 of 840) of the patients who did not receive antibiotic prophylaxis exhibited clinical signs of infection and received on-demand antibiotics within 14 days of UGI bleeding. Nevertheless, the RR of complications, including bacterial infection, rebleeding, and mortality, was not higher in the patients who did not receive antibiotic prophylaxis than in those who did. Notably, the overall infection rate was 4.9% (45 of 913 patients), which is low, despite the low rate of prophylactic antibiotic use; this suggests that the role of antibiotic prophylaxis is negligible in the patients with Child–Pugh class A/B cirrhosis and UGI bleeding. In the 45 patients with documented bacterial infection, the types and sites of infection were complex and not confined to gram-negative enteric bacteria (Table 4). The heterogeneous nature of the observed bacterial infections implicated that a broad-spectrum antibiotic should be implemented if a prophylactic regimen is intended to cover all potential pathogens.

In our study, patients with peptic ulcer bleeding received a short term intravenous PPI followed by oral PPI for 2–4 months. However, PPI use was suggested to increase the risk of SBP [22]. Although one multicenter prospective study indicated that PPI therapy does not increase the incidence of SBP in cirrhosis, PPIs should be administered after cautious evaluation of the indications in cirrhotic patients with UGI bleeding [23].

This was a retrospective study and thus has several limitations: First, we could not control for the confounding parameters; to resolve this, PPS matching was performed. Second, the prescriptions of antibiotics provided to our patients included cefazolin, cefazolin plus gentamicin, and cefuroxime and ceftriaxone; therefore, the use of antibiotic prophylaxis did not completely fit with the actual guidelines, which recommend quinolones or third-generation cephalosporins for 5–7 days after UGI bleeding. Third, no routine screening was performed for bacterial infections and therefore some occult infections may have been overlooked. Nevertheless, our findings revealed that even without routine infection workup and antibiotic use, the rate of clinically relevant infection was low. Fourth, distinguishing patients with Child–Pugh class B cirrhosis from those with class C cirrhosis can be challenging in a retrospective analysis because the factors, such as hepatic encephalopathy and ascites, are fairly subjective. Fifth, since transjugular intrahepatic portosystemic shunt has been unavailable in the study site, the impact of this therapeutic approach on the outcomes was lacking. Finally, data regarding the effects of prior bleeding episodes on patient outcomes could not be obtained because we enrolled patients with only initial UGI bleeding episodes.
Our study, nevertheless, suggests a low risk of bacterial infection in patients with low Child–Pugh scores and UGI bleeding, thus providing a rationale for additional randomized control trials comparing the differences in the effects of prophylactic versus on-demand antibiotic use in patients with low Child–Pugh scores and UGI bleeding.

**Conclusions**

In patients with Child–Pugh class A/B cirrhosis and UGI bleeding, bacterial infection risk is low, and antibiotic prophylaxis has minor effects on the major outcomes. To develop an effective antibiotic stewardship program and minimize side effects, on-demand antibiotic use may be an optimal strategy for these patients. Additional randomized control trials to confirm this finding are warranted.

**Supporting information**

S1 Table. Clinical outcomes of Child–Pugh Class A and B cirrhosis patients, with and without prophylactic antibiotic use.  
(DOCX)

S2 Table. Baseline patient characteristics in portal hypertensive patient subgroup.  
(DOCX)

S3 Table. Relative risks of clinical outcomes with respect to prophylactic antibiotic use in Child–Pugh Class A and B cirrhosis patients.  
(DOCX)

S4 Table. Factors associated with bacterial infection risk within 14 days in portal hypertensive patient subgroup.  
(DOCX)

S5 Table. Factors associated with risk of rebleeding within 14 days in portal hypertensive patient subgroup.  
(DOCX)

S6 Table. Factors associated with risk of mortality within 42 days in portal hypertensive patient subgroup.  
(DOCX)

S7 Table. Patient data of this study cohort.  
(XLSX)

**Author Contributions**

**Conceptualization:** Te-Sheng Chang, Ying-Huang Tsai, Wen-Shih Huang, Wei-Ming Chen, Yung-Yu Hsieh, Yu-Chih Wu, Shui-Yi Tung, Yen-Hua Huang.

**Data curation:** Te-Sheng Chang, Yi-Heng Lin, Chun-Hsien Chen, Chung-Kuang Lu, Yao-Hsu Yang.

**Formal analysis:** Te-Sheng Chang, Yi-Heng Lin, Chun-Hsien Chen, Chung-Kuang Lu, Yao-Hsu Yang.

**Investigation:** Te-Sheng Chang, Chun-Hsien Chen, Chung-Kuang Lu, Yao-Hsu Yang.

**Methodology:** Te-Sheng Chang, Shui-Yi Tung, Yen-Hua Huang.
Resources: Te-Sheng Chang, Chun-Hsien Chen, Chung-Kuang Lu, Yao-Hsu Yang.

Supervision: Shui-Yi Tung, Yen-Hua Huang.

Writing – original draft: Te-Sheng Chang, Ying-Huang Tsai, Shui-Yi Tung, Yen-Hua Huang.

Writing – review & editing: Wen-Shih Huang, Wei-Ming Chen, Yung-Yu Hsieh, Yu-Chih Wu, Shui-Yi Tung, Yen-Hua Huang.

References

1. Bonnel AR, Bunchorntavakul C, Reddy KR. Immune dysfunction and infections in patients with cirrhosis. Clin Gastroenterol Hepatol. 2011; 9:727–738. https://doi.org/10.1016/j.cgh.2011.02.031 PMID: 21987731

2. Jalan R, Fernandez J, Wiest R, Schnabl B, Moreau R, Angel P, et al. Bacterial infections in cirrhosis: a position statement based on the EASL Special Conference 2013. J Hepatol. 2014; 60:1310–1324. https://doi.org/10.1016/j.jhep.2014.01.024 PMID: 24530646

3. Runyon BA. Management of adult patients with ascites due to cirrhosis: An update. Hepatology. 2009; 49:2087–2107. https://doi.org/10.1002/hep.22853 PMID: 19475696

4. de Franchis R. Expanding consensus in portal hypertension: Report of the Baveno VI Consensus Workshop: Stratifying risk and individualizing care for portal hypertension. J Hepatol. 2015; 63:743–752. https://doi.org/10.1016/j.jhep.2015.05.022 PMID: 26047908

5. Hou MC, Lin HC, Liu TT, Kuo BI, Lee FY, Chang FY, et al. Antibiotic prophylaxis after endoscopic therapy prevents rebleeding in acute variceal hemorrhage: A randomized trial. Hepatology. 2004; 39:746–753. https://doi.org/10.1002/hep.20126 PMID: 14999693

6. Chavez-Tapia NC, Barrientos-Gutiérrez T, Tellez-Avila F, Soares-Weiser K, Mendez-Sanchez N, Gluud C, et al. Meta-analysis: Antibiotic prophylaxis for cirrhotic patients with upper gastrointestinal bleeding—an updated Cochrane review. Aliment Pharmacol Ther. 2011; 34:509–518. https://doi.org/10.1111/j.1365-2036.2011.04746.x PMID: 21707689

7. Moon AM, Dominitz JA, Ioannou GN, Lowy E, Beste LA. Use of antibiotics among patients with cirrhosis and upper gastrointestinal bleeding is associated with reduced mortality. Clin Gastroenterol Hepatol. 2016; 14:1623–1637. https://doi.org/10.1016/j.cgh.2016.05.046 PMID: 27311621

8. Shehab N, Patel PR, Sinivasan A, Budnitz DS. Emergency department visits for antibiotic-associated adverse events. Clin Infect Dis. 2008; 47:735–743. https://doi.org/10.1086/591126 PMID: 18694344

9. O’Leary JG, Reddy KR, Wong F, Kamath PS, Patton HM, Biggins SW, et al. Long-term use of antibiotics and proton pump inhibitors predict development of infections in patients with cirrhosis. Clin Gastroenterol Hepatol. 2015; 13:753–759.e752. https://doi.org/10.1016/j.cgh.2014.11.019 PMID: 25460564

10. Kamath PS, Mookerjee RP. Individualized care for portal hypertension: Not quite yet. J Hepatol. 2015; 63:543–545. https://doi.org/10.1016/j.jhep.2015.07.001 PMID: 26150255

11. Tandon P, Abraldes JG, Keough A, Bastianelli R, Jayakumar S, Carbonneau M, et al. Risk of bacterial infection in patients with cirrhosis and acute variceal hemorrhage, based on Child-Pugh class, and effects of antibiotics. Clin Gastroenterol Hepatol. 2015; 13:1189–1196. https://doi.org/10.1016/j.jch.2014.11.019 PMID: 25460564

12. Kong I, Augustin S, Pons M, Ventura-Cots M, González A, Esteban R, et al. Alcohol consumption and risk of infection after a variceal bleeding in low-risk patients. Liver Int. 2016; 36:994–1001. https://doi.org/10.1111/liv.13038 PMID: 26643967

13. Garcia-Tsao G, Groszmann RJ, Fisher RL, Conn HO, Atterbury CE, Glickman M. Portal pressure, presence of gastroesophageal varices and variceal bleeding. Hepatology. 1985; 5:419–424. https://doi.org/10.1002/hep.1840050313 PMID: 2873388

14. Boursier J, Cesbron E, Tropet AL, Pilette C. Comparison and improvement of MELD and Child-Pugh score accuracies for the prediction of 6-month mortality in cirrhotic patients. J Clin Gastroenterol. 2009; 43:580–585. https://doi.org/10.1097/MCG.0b013e31818189468 PMID: 19197195

15. Horan TC, Andrus M, Dudeck MA. CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting. Am J Infect Control. 2008; 36:309–332. https://doi.org/10.1016/j.ajic.2008.03.002 PMID: 18539899

16. Centers for Disease Control and Prevention. Antibiotic resistance threats in the United States, 2013. [Cited 2019 August 14]. Available from: http://www.cdc.gov/drugresistance/threat-report-2013/.
18. Deschênes M, Villeneuve JP. Risk factors for the development of bacterial infections in hospitalized patients with cirrhosis. Am J Gastroenterol. 1999; 94:2193–2197. https://doi.org/10.1111/j.1572-0241.1999.01293.x PMID: 10445549

19. Pauwels A, Mostefa-Kara N, Debenes B, Degoutte E, Levy V. Systemic antibiotic prophylaxis after gastrointestinal hemorrhage in cirrhotic patients with a high risk of infection. Hepatology. 1996; 24:802–806. https://doi.org/10.1002/hep.510240408 PMID: 8855179

20. Wu CK, Wang JH, Lee CH, Wu KL, Tai WC, Lu SN, et al. The outcome of prophylactic intravenous cefazolin and ceftriaxone in cirrhotic patients at different clinical stages of disease after endoscopic interventions for acute variceal hemorrhage. PLoS ONE. 2013; 8:e61666. https://doi.org/10.1371/journal.pone.0061666 PMID: 23630607

21. Lin HC, Lo GH, Perng DS, Lin CW, Tai CM. Compliance with antibiotic prophylaxis guidelines in patients with acute variceal bleeding. E-Da Med J. 2016; 3:9–16.

22. Abdel-Razik A, Abdelsalam M, Gad DF, Abdelwahab A, Tawfik M, Elzehery R, et al. Recurrence of spontaneous bacterial peritonitis in cirrhosis: novel predictors. Eur J Gastroenterol Hepatol. 2019 https://doi.org/10.1097/MEG.0000000000001578 [Epub ahead of print] PMID: 31851658

23. Terg R, Casciato P, Garbe C, Cartier M, Stieben T, Mendizabal M, et al. Proton pump inhibitor therapy does not increase the incidence of spontaneous bacterial peritonitis in cirrhosis: A multicenter prospective study. J Hepatol. 2015; 62:1056–1060. https://doi.org/10.1016/j.jhep.2014.11.036 PMID: 25481567